Paper Details

  1. Home
  2. Paper Details

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.

Author: BalkMark, BeerTomasz M, DevlinNancy, HerdmanMichael, HolmstromStefan, IvanescuCristina, LoriotYohann, NaidooShevani, ParliTeresa, PavesiMarco, PhungDe, TombalBertrand

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Enzalutamide delayed health-related quality of life (HRQoL) deterioration and had beneficial effects on several HRQoL domains, including Pain/Discomfort, compared with placebo in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. METHODS: Patients received oral enzalutamide 160 mg/day (n = 872) or ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481866/

データ提供：米国国立医学図書館（NLM）

Enzalutamide's Impact on Quality of Life in Metastatic Castration-Resistant Prostate Cancer

The journey of living with [metastatic castration-resistant prostate cancer (mCRPC)] can be a challenging desert trek. This study examines the effects of [enzalutamide], a [treatment] for [mCRPC], on [health-related quality of life (HRQoL)], using the [EQ-5D instrument] as a measure of patient well-being. The authors meticulously analyzed data from the [PREVAIL trial], much like a desert traveler carefully observing the terrain to navigate its challenges.

Enzalutamide's Positive Impact on Quality of Life in mCRPC

The study found that [enzalutamide] delayed [HRQoL deterioration] compared to [placebo], indicating a potential benefit for patients' overall well-being. Specifically, [enzalutamide] showed a slower decline in [EQ-5D index and EQ-5D VAS scores], suggesting that it might help patients maintain a better quality of life during their treatment journey. This finding is particularly encouraging, as [mCRPC] can significantly impact patients' daily lives, much like a harsh desert can test the limits of a traveler's endurance.

Navigating mCRPC with Enzalutamide: Potential for Improved Quality of Life

This study suggests that [enzalutamide] could play a crucial role in improving [HRQoL] for patients with [mCRPC]. By mitigating the negative impact of the disease on [pain, discomfort, anxiety, depression, and mobility], [enzalutamide] could help patients navigate the challenges of their condition with greater ease. It's like finding a refreshing oasis in the midst of a scorching desert, providing respite and support for those who need it most.

Dr. Camel's Conclusion

This study highlights the importance of considering [HRQoL] in the treatment of [mCRPC]. By demonstrating the potential benefits of [enzalutamide] on [HRQoL], this research sheds light on a promising avenue for improving the overall well-being of patients. Much like a wise desert traveler seeks out resources to ease their journey, researchers must continue to explore ways to enhance the quality of life for those living with [mCRPC].

Date :
  1. Date Completed 2017-10-20
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

28645287

DOI: Digital Object Identifier

PMC5481866

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.